Early life and adult exposure to isoflavones and breast cancer risk

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 26, Issue 2, 2008, Pages 113-173

  Tomar, Rajpal S ^a   Shiao, Renee ^a  

^a CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Breast cancer; Early life exposure; Isoflavone; Phytoestrogen; Risk assessment

Indexed keywords

FOOD ADDITIVES; HEALTH RISKS; VITAMINS;

ANIMAL STUDIES; BREAST CANCER RISK; BREAST CANCERS; CONFLICTING EVIDENCE; DIETARY INTAKES; DIETARY SUPPLEMENTS; ESTROGEN RECEPTOR (ER); HEALTH BENEFITS; HEART DISEASES; ISOFLAVONE; ISOFLAVONES; NORTH AMERICA; PROCESSED FOODS; SOY ISOFLAVONES; SOY PRODUCTS;

NUTRITION;

ISOFLAVONE DERIVATIVE; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; EPIDEMIOLOGICAL DATA; ESTROGEN ACTIVITY; EXPERIMENTAL ANIMAL; EXPOSURE; FOOD INTAKE; HUMAN; NONHUMAN; RED CLOVER; REVIEW; SOYBEAN; SPECIES DIFFERENCE; ANIMAL; BREAST TUMOR; CHEMISTRY; CLOVER; DISEASE MODEL; DOSE RESPONSE; FEMALE; RISK ASSESSMENT; RISK FACTOR; SAFETY; TIME;

ANIMALIA; TRIFOLIUM PRATENSE;

ANIMALS; BREAST NEOPLASMS; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOFLAVONES; PHYTOESTROGENS; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SOYBEANS; SPECIES SPECIFICITY; TIME FACTORS; TRIFOLIUM;

EID: 46749100559     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590500802074256     Document Type: Review

References (233)

1. Adlercreutz H, van der Wildt J, Kinzel J, Attalla H, Wahala K, Makela T, Hase T, Fotsis T. Lignan and isoflavonoid conjugates in human urine. J Steroid Biochem Mol Biol 1995;52:97-103.
2. Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 2000;71:1705S-7S.
3. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 2005;15:17-22.
4. Adlercreutz H, Heinonen SM, Penalvo-Garcia J. Phytoestrogens, cancer and coronary heart disease. Biofactors 2004;22:229-36.
5. Zhang X, Shu XO, Gao Y, Yang G, Li Q, Li H, Jin F, Zheng W. Soy food consumption is associated with lower risk of coronory heart disease in Chinese women. J Nutr 2003;133:2874-8.
6. Park OJ, Surh Y. Chemopreventive potential of epigallocatechin gallatge and genistein: evidence from epidemiological and laboratory studies. Tox Lett 2003;150:43-56.
7. Limer JL, Speirs V. Phytoestsrogen and breast cancer chemoprevention. Breast Cancer Res 2004;6:119-127.
8. FDA, Food labeling: Health claim; Soy Protein and coronory Heart Disease.Federal Register. 21CFR Part 1011999. p. http://www.cfsan.fda.gov/.
9. Arena S, Rappa C, Del Frate E, Cenci S, Villani C. A natural alternative to menopausal hormone replacement therapy. Phytoestrogens. Minerva Ginecol 2002;54:53-7.
10. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, and Winston M. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler Thromb Vasc Biol 2006;26:1689-92.
11. FDA. Docket # 2004Q-0151 Solae Company Health Claim on Cancer. 2005.
12. Cerhan JR, Kushi LH, Olson JE, R.S. S., Zheng W, Folsom AR, and Seller TA. Twinship and risk of postmenopausal breast cancer. J Natl Cancer Inst 2000;92:261-265.
13. Ekbom A, Hsieh CC, Lipworth L, Adami HQ, and Trichopoulos D. Intrauterine environment and breast cancer risk in women: a population-based study. J Natl Cancer Inst 1997;89:71-6.
14. Sanderson M, Williams MA, Malone KE, Stanford JL, Emanul L, White E, and Daling JR. Perinatal factor and risk of breast cancer. Epidemiology 1996;7:34-57.
15. Weir BE, Marrett LD, Kreiger N, Darlington GA, and Sugar L. Pre-natal and perinatal exposure and risk of testicular germ cell cancer. International Journal of cancer 2000;87:438-443.
16. Abe T. Infantile leukemia and soybean - a hypothesis. Leukemia 1998;13:317-320.
17. Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP, Dowsett M, Welch AA, Khaw KT, Wareham NJ, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 2004;13:698-708.
18. Lampe JW, Gustafson DR, Hutchins AM, Martini MC, Li S, Wahala K, Grandits GA, Potter JD, Slavin JL. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 1999;8:699-707.
19. Valentin-Blasini L, Sadowski MA, Walden D, Caltabiano L, Needham LL, Barr DB. Urinary phytoestrogen concentrations in the U.S. population (1999-2000). J Expo Anal Environ Epidemiol 2005;15:509-23.
20. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AMY, West DW. Migration pattern and breast cancer risk in asian american women. J Natl Cancer Inst 1993;85:1819-1827.
21. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002;360:861-868.
22. Coglino VJ, GrosseBaan R, Straif K, Secretan B, Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptive and menopausal treatment. Lancet 2005;6:552-553.
23. Cos P, de Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogen recent development. Planta Med 2003;69:589-599.
24. Branca F, Lorenzetti S. Health effects of phytoestrogens. Forum 2005;100-11, 100-11.
25. Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health. Phytochemistry 2004;65:995-1016.
26. UK-Committee-on-toxicity. Phytoestsrogen and healt. London U.K.Committe on Toxicity of Chemicals in Food, Consumer Product and the Environment; 2003.
27. Thompson LU, Robb P, Serriano M, Cheung F. Mammalian lignan production from various food. Nutr Cancer 1991;16:43-52.
28. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993;101:378-84.
29. Steensma A, Faassen-Peters MA, Noteborn HP, Rietjens IM. Bioavailability of genistein and its glycoside genistin as measured in the portal vein of freely moving unanesthetized rats. J Agric Food Chem 2006;54:8006-12.
30. Setchell KD, Brown NM, E. Lydeking-Olson. The clinical importance of metabolite equol - A clue to the effectiveness of soy and its isoflavone. The Journal of Nurituion 2002;132:3577-3584.
31. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005;230:155-70.
32. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131:1362S-75S.
33. Rozman KK, Bhatia J, Calafat AM, Chambers C, Culty M, Etzel RA, Flaws JA, Hansen DK, Hoyer PB, Jeffery EH, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of soy formula. Birth Defects Res B Dev Reprod Toxicol 2006;77:280-397.
34. Heinonen SM, Hoikkala A, Wahala K, Adlercreutz H. Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J Steroid Biochem Mol Biol 2003;87:285-99.
35. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-9.
36. Frankenfeld CL, Atkinson C, Thomas WK, Gonzalez A, Jokela T, Wahala K, Schwartz SM, Li SS, Lampe JW. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 2005;94:873-6.
37. Bowey E, Adlercreutz H, Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol 2003;41:631-6.
38. Nagel SC, vom Saal FS, Welshons WV. The effective free fraction of oestradiol and xenoestroges in human serum measured by whole cel uptake assay: physiology of delivery modifies oestrogen acitvity. Proc Soc Exp Biol Med 1998;217:300-309.
39. Zhao JH, Sun SJ, Arao Y, Oguma E, Yamada K, Horiguchi H, Kayama F. Identification of equol producers in a Japanese population by high-performance liquid chromatography with coulometric array for determining serum isoflavones. Phytomedicine 2006;13:304-9.
40. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, Jones K, Moore R, Ogden LG, Wahala K, Sackett HM, et al. Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in caucasian men. J Nutr 2005;135:1400-6.
41. Song KB, Atkinson C, Frankenfeld CL, Jokela T, Wahala K, Thomas WK, Lampe JW. Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J Nutr 2006;136:1347-51.
42. Simons AL, Renouf M, Hendrich S, Murphy PA. Metabolism of glycitein(7,4′-dihydroxy-6-methoxyisoflavone by human gut microflora. Agriculture and Food Chemistry 2005;53:8519-8525.
43. Roberts DW, doerge DR, Churchwell MI, da Costa GG, Marques MM, Tolleson WH. Inhibition of extrahepatic human cytochrome P450 1A1 and 1B1 by metabolism of isoflavone found in Trifolium pratense (Red Clover). J Agric Food Chem 2004;52:6623-6632.
44. Cassidy A, Brown JE, Hawdon A, Faughnan MS, King LJ, Millward J, Zimmer-Nechemias L, WolfeB, Setchell KD. Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr 2006;136:45-51.
45. Kano M, Takayanagi T, Harada K, Sawada S, Ishikawa F. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr 2006;136:2291-6.
46. Zubik L, Meydani M. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am J Clin Nutr 2003;77:1459-65.
47. Gu L, House SE, Prior RL, Fang N, Ronis MJ, Clarkson TB, Wilson ME, Badger TM. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J Nutr 2006;136:1215-21.
48. Nation Soy Bean Research Laboratory. ( http://www.nsrl.uiuc.edu)
49. Wang HJ, Murphy PA. Isoflavone content in comercial soybean foods. J. Agri Food Chemistry 1994;42:1666-73.
50. Franke AA, Halm BM, Custer LJ, Tatsumura Y, Hebshi S. Isoflavones in breastfed infants after mothers consume soy. Am J Clin Nutr 2006;84:406-13.
51. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 1994;86:1076-82.
52. Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002;132:3168-71.
53. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phytooestrogens in Japanese men. Lancet 1993;342:1209-10.
54. Xu X, Wang HJ, Murphy PA, Cook L, Hendrich S. Daidzein is a more bioavailable soy milk isoflavone than is genistein in adult women. The Journal of Nutrition 1994;124:825-832.
55. Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V, Heubi JE. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 2003;133:1027-35.
56. Setchell KD, Zimmer-Nechemias L, Cal J, Heubl JE. Exposure of infants to phtoestrogen from soy-based infant formula. Lancet 1997;350:23-27.
57. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 1998;68:1453S-1461S.
58. Adlercreutz H, Yamada T, Wahala K, Watanabe S. Maternal and neonatal phytoestrogens in Japanese women during birth. Am-J-Obstet-Gynecol 1999;180:737-43.
59. Todaka E, Sakurai K, Fukata H, Miyagawa H, Uzuki M, Omori M, Osada H, Ikezuki Y, Tsutsumi O, Iguchi T, et al. Fetal exposure to phytoestrogens - the difference in phytoestrogen status between mother and fetus. Environ Res 2005;99:195-203.
60. Foster WG, Chan S, Platt L, Hughes, Jr. CL. Detection of phytoestrogens in samples of second trimester human amniotic fluid. Toxicol Lett 2002;129:199-205.
61. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000;74:279-85.
62. Hall JM, Couse JF, Korach KS. The multifaceted mechanims of estradiol and estrogen receptor signaling J Biol Chem 2001;276:36869-72.
63. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999;13:1672-85.
64. Bjornstrom L, Sjoberg M. Mechanism of estrogen receptor signaling: convergence of genomic and nongenomic action on target cells. Mol Endocrinol 2005;19:833-842.
65. Song RX, Santen RJ. Membrane initiated estrogen signaling in breast cancer. Biol Reprod 2006;75:9-16.
66. Ikeda K, Inoue S. Estrogen receptors and their downstream targets in cancer. Arch 2004;67:435-42.
67. Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogen and cell- cycle regulation in breast cancer. trends Endocrinol Metab 2001;12:320-327.
68. Kuiper GG, Lemmen JG, Carlson B, Conron JC, Safe SH, van der Saag PT, Vaca CE, van der Burg B, Gustafson JA. Ineractin of estrogenic chemicals and phytoestrogen with estgrogen receptor beta. Endocrinol 1998;139:4252-4263.
69. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol 2004;80:14-25, 14-25. Epub 2004 Apr 14.
70. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, et al. Estrogen receptor beta in breast cancer. Endocr 2002;9:1-13.
71. Safe S, McDougal A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int 2002;20:1123-8.
72. Allan DJ, Howell A, Roberts SA, Williiams GT, Watson RJ, Coyne JD, Clarke RB, Laidlaw, IJ, Potten CS. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathology 1992;167:25-32.
73. Kihara S, Nehlsen-Cannarella N, Kirsch WM, Chase D, Garvin AJ. A comparative study of apoptosis and cell proliferation in infantile and adult fibrosarcomas. Am J Clin Pathol 1996;106:493-7.
74. Khan SA, Bhandra D, R.T. Chatterton Jr. The local hormone environment and related biomarkers in the normal breast. Endocrine-related Cancer 2005;12:497-510.
75. Cecconi F, Gruss P. Apaf1 in developmental apoptosis and cancer: how many ways to die? Cell Mol Life Sci 2001;58:1688-97.
76. Crawford RA, Caldwell C, Iles RK, Lowe D, Shepherd JH, Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 1998;78:210-4.
77. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;41:342-348.
78. Frank SA. Genetic predisposition to cancer - insights from population genetics. Nat 2004;5:764-72.
79. Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol. 2004;546:121-65.
80. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer Incidence in Five Continents Vol. VIIIIARC Scientific Publication No. 155, 2003.
81. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 2003;77:171-83.
82. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 2006;89:1121-34.
83. Messina M, McCaskill-Stevens W, Lampe W. Addressing the soy and breast cancer relationship. Review, Commentry, and workshop proceedings. Journal of the national cancer institute 2006;98:1275-1283.
84. Rice S, Whitehead SA. Phytoestrogen and breat cancer - promoters or protectors? Endocrine-related Cancer 2006;13:995-1015.
85. Key TJ, Sharp GB, Appleby PN. Soy foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999;81:1248-1256.
86. Greenstein J, Kushi LH, Zheng W. Risk of breat cancer associated with intake of specific food groups. Am J Epidemiology 1996;143:S36.
87. Horn-Ross PL, Hoggatt KLJ, West DW, Krone MR, Stewart SL, Anton H, Ba GN, Bernstein L, Deapen D, Peel D, et al. Recent diets and breast cancer risk: California Teacher Study. Cancer Causes Control 2002;13:407-415.
88. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 2003;95:906-13.
89. Travis RC, Allen NE, Appleby PN, Spencer EA, Roddam AW, Key TJ. A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer 2008;122:705-10.
90. Nishio K, Niwa Y, Toyoshima H, Tamakoshi K, Kondo T, Yatsuya H, Yamamoto A, Suzuki S, Tokudome S, Lin Y, et al. Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study. Cancer Causes Control 2007;18:801-8.
91. Touillaud MS, Thiebaut AC, Niravong M, Boutron-Ruault MC, Clavel-Chapelon F. No association between dietary phytoestrogens and risk of premenopausal breast cancer in a French cohort study. Cancer Epidemiol Biomarkers Prev 2006;15:2574-6.
92. den Tonkelaar I, Keinan-Boker L, Veer PV, Arts CJ, Adlercreutz H, Thijssen JH. Urinary phytoestrogen and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10.
93. Keinan BL, Der Schouw YT, Grobbee DE, Peeters PH. Dietary phytoestrogen and breast cancer. Amer J Clinical Nutrition 2004;79:282-288.
94. Witte JS, Ursin G, Siemiatycki J, Thompson WD, Paganini-Hill A, Haile RW. Diet and premenopausal bilateral breast cancer: a case-control study. Breast Cancer Res Treat 1997;42:243-51.
95. Thanos J, Cotterchio M, Boucher BA, Kreiger N, Thompson LU. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 2006;17:1253-61.
96. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006;98:459-71.
97. Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao YT, Zheng W. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001;10:483-8.
98. Dai Q, Shu XO, Jin F, Potter JD, Kushi LH, Teas J, Gao YT, Zheng W. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001;85:372-8.
99. Dai Q, Franke AA, Yu H, Shu XO, Jin F, Hebert JR, Custer LJ, Gao YT, Zheng W. Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiol Biomarkers Prev 2003;12:497-502.
100. Wu AH, Ziegler RG, Horn-Ross PL, Nomura AM, West DW, Kolonel LN, Rosenthal JF, Hoover RN, Pike MC. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 1996;5:901-6.
101. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-6.
102. Badger TM, Ronis MJ, Simmen RC, Simmen FA. Soy protein isolate and protection against cancer. J Am Coll Nutr 2005;24:146S-149S.
103. Qin LQ, Xu JY, Wang PY, Hoshi K. Soyfood intake in the prevention of breast cancer risk in women: a meta-analysis of observational epidemiological studies. J Nutr Sci Vitaminol (Tokyo) 2006;52:428-36.
104. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008;98:9-14.
105. USDA, U.S. Department of Agriculture, Agricultural Research Service. 2002. USDA-Iowa State University Database on the Isoflavone Content of Foods., Release 1.3-2002.
106. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006;55:1-12.
107. Cassidy A, Bingham S, Setchell KD. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 1994;60:333-40.
108. Yeole BB, Jayant K, Jussawalla DJ. Trends in breast cancer incidence in greater Bombay: an epidemiological assessment. Bull World Health Organ 1990;68:245-9.
109. Yang G, Shu XO, Jin F, Zhang X, Li HL, Li Q, Gao YT, Zheng W. Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Am J Clin Nutr 2005;81:1012-7.
110. Yoo KY, Kim Y, Park SK, Kang D. Lifestyle, genetic susceptibility and future trends of breast cancer in Korea. Asian Pac J Cancer Prev 2006;7:679-82.
111. Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D, Hisamichi S. The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer 2004;108:901-6.
112. Yeole BB, Kurkure AP. An epidemiological assessment of increasing incidence and trends in breast cancer in Mumbai and other sites in India, during the last two decades. Asian Pac J Cancer Prev 2003;4:51-6.
113. Minami Y, Ohuchi N, Fukao A, Hisamichi S. Risk factors for breast cancer: a case-control study of screen-detected breast cancer in Miyagi Prefecture, Japan. Breast Cancer Res Treat 1997;44:225-33.
114. Dimitrakakis C, Gosselink L, Gaki V, Bredakis N, Keramopoulos A. Phytoestrogen supplementation: a case report of male breast cancer. Eur 2004;13:481-4.
115. Pumford SL, Morton MM, Turkes A, Griffiths K. Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry. Ann Clin Biochem 2002;39:281-92.
116. Minami Y, Ohuchi N, Taeda Y, Fukao A, Hisamichi S. Risk factors for benign breast disease according to histopathological type: comparisons with risk factors for breast cancer. Jpn J Cancer Res 1998;89:116-23.
117. Ganmaa D, Sato A. The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Med Hypotheses 2005;65:1028-37.
118. Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer 2002;94:1166-74.
119. Lu LJ, Anderson KE, Grady JJ, Kohen F, Nagamani M. Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res 2000;60:4112-21.
120. Atkinson C, Skor HE, Dawn Fitzgibbons E, Scholes D, Chen C, Wahala K, Schwartz SM, Lampe JW. Urinary equol excretion in relation to 2-hydroxyestrone and 16alpha-hydroxyestrone concentrations: an observational study of young to middle-aged women. J Steroid Biochem Mol Biol 2003;86:71-7.
121. Nagata C, Takatsuka N, Shimizu H, Hayashi H, Akamatsu T, Murase K. Effect of soymilk consumption on serum estrogen and androgen concentrations in Japanese men. Cancer Epidemiol Biomarkers Prev 2001;10:179-84.
122. Nagata C, Iwasa S, Shiraki M, Ueno T, Uchiyama S, Urata K, Sahashi Y, Shimizu H. Associations among maternal soy intake, isoflavone levels in urine and blood samples, and maternal and umbilical hormone concentrations (Japan). Cancer Causes Control 2006;17:1107-13.
123. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86.:225-30.
124. Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999;84:4017-24.
125. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M, Coward L. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996;5:785-94.
126. McMichael-Phillips DF, Hardign C, Morton M, Roberts SA, Howell A, Potten CS, Bundred NJ. Effect of soy-protein supplementation on epitelial proliferation in the histologycally normal breast.. Am J Clin Nutr 1998;68:1434s-1436s.
127. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, Nolan C, Coombes RC. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51:1817-22.
128. Peterson OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor positive cells in normal and nonlactating human breast. Cancer Research 1987;47:5748-5751.
129. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998;90:37-42.
130. Lawson JS, Field AS, Champion S, Tran D, Ishikura H, Trichopoulos D. Low estrogen recptor alpha expression in normal breast tissue underlies low breast cancer incidence in Japan. The lancet 1999;354.
131. Cohen LA, Zhao Z, Pittman B, Scimeca JA. Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis. Carcinogenesis 2000;21:929-35.
132. Zaizen Y, Higuchi Y, Matsuo N, Shirabe K, Tokuda H, Takeshita M. Antitumor effects of soybean hypocotyls and soybeans on the mammary tumor induction by N-methyl-n-nitrosourea in F344 rats. Anticancer Res 2000;20:1439-44.
133. NTP. Toxicology and Carcinogenesis Studies of Genistein (CAS No. 446-72-0) in Sprague-Dawley Rats (Feed Study). 2006.
134. Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phytooestrogens and breast cancer. Lancet 1997;350:990-4.
135. Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, Korol DL, Wallig MA, Helferich WG. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 2004;25:211-8.
136. Ueda M, Niho N, Imai T, Shibutani M, Mitsumori K, Matsui T, Hirose M. Lack of significant effects of genistein on the progression of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. Nutr Cancer 2003;47:141-7.
137. Mehta R, Lok E, Caldwell D, Mueller R, Kapal K, Taylor M, Cooke GM, Curran IH. Mammary gland tumor promotion in F1 generation offspring from male and female rats exposed to soy isoflavones for a lifetime. J AOAC Int 2006;89:1197-206.
138. Lamartiniere CA, Moore J, Holland M, Barnes S. Neonatal genistein chemoprevents mammary cancer. Proc Soc Exp Biol Med 1995;208:120-3.
139. Lamartiniere CA. Timing of exposure and mammary cancer risk. J 2002;7. 7:67-76.
140. Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis 1998;19:2151-8.
141. Murrill WB, Brown NM, Zhang JX, Manzolillo PA, Barnes S, Lamartiniere CA. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 1996;17:1451-7.
142. Hilakivi-Clarke L, Onojafe I, Raygada M, Cho E, Skaar T, Russo I, Clarke R. Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br 1999;80:1682-8.
143. Badger TM, Ronis MJ, Hakkak R. Developmental effects and health aspects of soy protein isolate, casein, and whey in male and female rats. Int J Toxicol 2001;20:165-74.
144. Hakkak R, Korourian S, Shelnutt SR, Lensing S, Ronis MJ, Badger TM. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. Cancer Epidemiol Biomarkers Prev 2000;9:113-7.
145. Simmen RC, Eason RR, Till SR, Chatman Jr, L, Velarde MC, Geng Y, Korourian S, Badger TM. Inhibition of NMU-induced mammary tumorigenesis by dietary soy. Cancer Lett 2005;224:45-52.
146. Constantinou AI, Mehta RG, Vaughan A. Inhibition of N-methyl-N- nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer 1996;16:3293-8.
147. Constantinou AI, Lantvit D, Hawthorne M, Xu X, van Breemen RB, Pezzuto JM. Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr 2001;41:75-81.
148. Constantinou AI, White BE, Tonetti D, Yang Y, Liang W, Li W, van Breemen RB. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer 2005;41:647-54.
149. Barnes S, Grubbs C, Setchell KD, N.S. C., N.S. C., Carlson J. Soybean inhibit mammry tumors in models of breast cancer. Mutagens and carcinogens in the diet. 1990: Wiley-Liss, Inc. 239-253.
150. Barnes S, Peterson G, Potential Role of Dietary Isoflavones in the Prevention of Cancer Diet and Cancer: Markers, Prevention and Treatment. M.M. Jacob. (ED.) 1994, New York: Plenum Press.
151. Troll W, Wiesner R, Shellabarger CJ, Holtzman S, Stone P. Soybean diet lowers breast tumors incidence in irradiated rats. carcinogenesis 1980;1:469472.
152. Gallo D, Giacomelli S, Cantelmo F, Zannoni GF, Ferrandina G, Fruscella E, Riva A, Morazzoni P, Bombardelli E, Mancuso S, et al. Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. Breast Cancer Res Treat 2001;69:153-64.
153. Gridley DS, Kettering JD, Slater JM, Nutter RL. Modification of spontaneous mammary tumors in mice fed different sources of protein, fat and carbohydrate. Cancer Lett 1983;19:133-46.
154. Gallo D, Ferlini C, Fabrizi M, Prislei S, Scambia G. Lack of stimulatory activity of a phytoestrogen-containing soy extract on the growth of breast cancer tumors in mice. Carcinogenesis 2006;27:1404-9.
155. Jin Z, MacDonald RS. Soy isoflavones increase latency of spontaneous mammary tumors in mice. J 2002;132:3186-90.
156. Thompson AR, Mortensen A, Breinholt VM, Lindecrona RH, Penalvo JL, Sorensen IK. Influence of prevastein, an isoflavone-rich soy product on mammry gland development and tumoroigenesis in T.gNK 9MMTV/c-neu) mice. Nutrition Cancer 2005;52:176-188.
157. Day JK, Besch-Williford C, McMann TR, Hufford MG, Lubahn DB, MacDonald RS. Dietary genistein increased DMBA-induced mammary adenocarcinoma in wild-type, but not ER alpha KO, mice. Nutr Cancer 2001;39:226-32.
158. Yan L, Li D, Yee JA. Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice. Clin Exp Metastasis 2002;19:535-40.
159. Connolly JM, Liu XH, Rose DP. Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice. Nutr Cancer 1997;29:48-54.
160. Hewitt AL, Singletary KW. Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model. Cancer Lett 2003;192:133-43.
161. Luijten M, Thomsen AR, van den Berg JA, Wester PW, Verhoef A, Nagelkerke NJ, Adlercreutz H, van Kranen HJ, Piersma AH, Sorensen IK, et al. Effects of soy-derived isoflavones and a high-fat diet on spontaneous mammary tumor development in Tg.NK (MMTV/c-neu) mice. Nutr 2004;50:46-54.
162. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957-62.
163. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 2006;27:856-63.
164. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833-8.
165. Conolly RB, Kimbell JS. Computer simulation of cell growth governed by stochastic processes: application to clonal growth cancer models. Toxicol Appl Pharmacol 1994;124:284-95.
166. Preston RJ. Children as a sensitive subpopulation for the risk assessment process. Toxicol Appl Pharmacol 2004;199:132-41.
167. Ginsberg GL. Assessing cancer risks from short-term exposures in children. Risk Anal 2003;23:19-34.
168. Anderson LM, Diwan BA, Fear NT, Roman E. Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect 2000;108 Suppl 3:573-94.
169. Barton HA, Cogliano VJ, Flowers L, Valcovic L, Setzer RW, Woodruff TJ. Assessing susceptibility from early-life exposure to carcinogens. Environ 2005;113. 113:1125-33, 1125-33.
170. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.
171. Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, Kaufman R, Herbst AL, Noller KL, Hyer M, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1509-14.
172. Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006;36 Suppl 14:121-5.
173. EPA, US. Supplemetal Guidance for Assessing Cancer Susceptibility from Early-Life Exposure to Carcinogen., D.C.E.R.-F. Washington, Editor. 2005.
174. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89-96.
175. Anbazhagan R, Gusterson A. Prenatal factors may influence predisposition to breast cancer. European Journal of Cancer 1994;1.
176. Brody JG, Rudel RA. Environmental pollutants and breast cancer. Environ Health Perspect 2003;111:1007-19.
177. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 2003;111:389-94.
178. Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet 1990;335. 335:939-40, 939-40.
179. Potischman N, Troisi R. In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 1999;10:561-73.
180. Clemons M, Goss P. Estrogen and the risk of breast cancer. The New England Journal of Medicine 2001;344:276-284.
181. Henderson BE, Endogenous and exogenous endocrine factor. In Diagnosis and Therarpy of Breast Cacner, 1989. p. 577-597.
182. Howard BA, Gusterson BA. Human breast development. J Mammary Gland Biol Neoplasia 2000;5:119-37.
183. Jolicoeur F. Intrauterine breast development and the mammary myoepithelial lineage. Jounal of Mammry Gland Biology and Neoplasia 2006;10:199-209.
184. Woodward WA, Chen MS, Behbod F, Rosen JM. On mammary stem cell. Journal of Cell Science 2005;118:3585-3594.
185. Baik I, Devito WJ, Ballen K, Becker PS, Okulicz W, Liu Q, Delpapa E, Lagiou P, Sturgeon S, Trichopoulos D, et al. Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer 2005;65. 65:358-63, 358-63.
186. Munoz-Valle JF, Vazquez-Del Mercado M, Garcia-Iglesias T, Orozco-Barocio G, Bernard-Medina G, Martinez-Bonilla G, Bastidas-Ramirez BE, Navarro AD, Bueno M, Martinez-Lopez E, et al. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol 2003;131:377-84.
187. Agriculture, U.D.O. Modification of the vegetable protein products requirements for the National School Lunch Program, School Breakfast program, Summer Food Service Program and Child and Adult Care Food Program. Fed Reg 2000;7:12429-12442.
188. NHANES. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2002.http://www.cdc.gov/nchs/about/major/ nhanes/datalink.htm.
189. Messina M, Messina V. Provisional Recommended Soy Protein and Isoflavone Intakes for Healthy Adults: Rationale. Nutr Today 2003;38:100-109.
190. Hilakivi-Clarke L, Cho EN, Cabanes A, De Assis S, Oliva S, Helferich WG, Lippman M, Clarke R. Dietary modulaton of pregnancy estrogen levels and breast cancer risk among rat offspring. Clinical Cancer Research 2002;8:3601-3610.
191. Titus-Ernstoff L, Hatch EE, Hoover RN, Palmer J, Greenberg ER, Ricker W, Kaufman R, Noller K, Herbst AL, Colton T, et al. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Br J Cancer 2001;84:126-33.
192. Preston-Martin S. Epidemiological studies of perinatal carcinogenesis. IARC Sci Publ 1989;289-314.
193. Schrager S, Potter BE. Diethylstilbestrol exposure. Am Fam Physician 2004;69:2395-400.
194. Newbold RR, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res 1990;50:7677-81.
195. Diwan BA, Kasprzak KS, Anderson LM. Promotion of dimethylbenz(a) anthracene-initiated mammary carcinogenesis by iron in female Sprague-Dawley rats. Carcinogenesis 1997;18:1757-62.
196. Iarc. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Pharmaceutical Drugs. IARC, Lyon, France. 1996;66:253-365.
197. Carthew P, Edwards RE, Nolan BM, Martin EA, Heydon RT, White IN, Tucker MJ. Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 2000;21:793-7.
198. Carthew P, Martin EA, White IN, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer 1995;55:544-7.
199. Newbold RR, Hanson RB, Jefferson WN, Bullock BC, Haseman J, McLachlan JA. Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis 2000;21:1355-63.
200. Bullock BC, Newbold RR, McLachlan JA. Lesions of testis and epididymis associated with prenatal diethylstilbestrol exposure. Environ Health Perspect 1988;77:29-31.
201. Li S, Hursting SD, Davis BJ, McLachlan JA, Barrett JC. Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann 2003;983:161-9.
202. Rajapakse N, Silva E, Kortenkamp A. Combining Xenoestrogens at Levels below Individual No-Observed-Effect Concentrations Dramatically Enhances Steroid Hormone Action. Environ 2002;110:917-21.
203. Payne J, Scholze M, Kortenkamp A. Mixtures of four organochlorines enhance human breast cancer cell proliferation. Environ 2001;109:391-7.
204. van Meeuwen JA, van den Berg M, Sanderson JT, Verhoef A, Piersma AH. Estrogenic effects of mixtures of phyto- and synthetic chemicals on uterine growth of prepubertal rats. Toxicol Lett 2007;170:165-76.
205. Tinwell H, Ashby J. Sensitivity of the immature rat uterotrophic assay to mixtures of estrogens. Environ Health Perspect 2004;112:575-82.
206. You L, Casanova M, Bartolucci EJ, Fryczynski MW, Dorman DC, Everitt JI, Gaido KW, Ross SM, Heck H. Hd. Combined effects of dietary phytoestrogen and synthetic endocrine- active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor. Toxicol Sci 2002;66:91-104.
207. Wolff MS, Teitelbaum SL, Windhaum G, Pinney SM, Britton JA, Chelimo C, Godbold J, Biro F, Kushi LH, Pfeiffer CM, et al. Pilot study of Urinary biomarkers of phytoestrogen, phthalates, and phenols in girls. Envronmental Health Prospective 2007;115:116-121.
208. Wang RY, Needham LL, Barr DB. Effect of environmental agent on the attainment of puberty consideration when assissing expsoure to environmental chemicals in the National Children's Study. Environmetnal Health Perspective 2005;113:1100-1106.
209. Wang XJ, Bartoulucci-Page E, Fenton SE, You L. Altered mammary gland development in male rats exposed to genistein adn methoxyclor Toxicological Sciences 2006;91:93-103.
210. Foster WG, Younglai EV, Boutross-Tadross O, Hughes CL, Wade MG. Mammary gland morphology in Sprague-Dawley rats following treatment with an organochlorine mixture in utero and neonatal genistein. Toxicol Sci 2004;77:91-100.
211. Russo J, Balogh G, Russo IH. Breast cancer prevention. Climacteric 2007;10 Suppl 2:47-53.
212. Lee HP, Gourley L, Duff SW, j. Esteve, Lee J, Day NE. Risk factor for breast cancer by age and menopausal status: a case-control study in singapore 1992;3:313-22.
213. Hirose K, Takima K, Hamajima N, Inoue M, Takezaki T, Kuroisha K, Yoshida M, Tokudome S. A large scale hospital basedcase-control study of risk factors of breast canceraccording to menopausal status. Jpn J Cancer Res 1995;86:146-154.
214. Hirose K, Imaeda N, Tokudome Y, Goto C, Wakai K, Matsuo K, Ito H, Toyama T, Iwata H, Tokudome S, et al. Soybean products and reduction of breast cancer risk: a case-control study in Japan. Br J Cancer 2005;93:15-22.
215. Wu AH, Stanczyk FZ, Seow A, Lee HP, Yu MC. Soy intake and other lifestyle determinants of serum estrogen levels among postmenopausal Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev 2002;11:844-51.
216. Yuan JM, Wang QS, Ross RK, Henderson BE, Yu MC. Diet and breast cancer in Shanghai and Tianjin, China. Br J Cancer 1995;71:1353-8.
217. Chie WU, Lee WC, Li CY, Huang CS, Lin RS, and Soybean products vegetable and fruits and breast cancer risk in Taiwan. Breast Cancer Research Treatment 1997;46:80 (abstract).
218. Zheng W, Dai Q, Custer LJ, Shu XO, Wen WQ, Jin F, Franke AA. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:35-40.
219. Do MH, Lee SS, Kim JY, Jung PJ, Lee MH. Fruits vegetables, soy foods and breast cancer in pre- and postmenopausal Korean women: a case-control study. Int J Vitam Nutr Res 2007;77:130-41.
220. Shannon J, Ray R, Wu C, Nelson Z, Gao DL, Li W, Hu W, Lampe J, Horner N, Satia J, et al. Food and botanical groupings and risk of breast cancer: a case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2005;14:81-90.
221. Linseisen J, Piller R, Hermann S, Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int 2004;110. 110:284-90.
222. Bosetti C, Spertini L, Parpinel M, Gnagnarella P, Lagiou P, Negri E, Franceschi S, Montella M, Peterson J, Dwyer J, et al. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol Biomarkers Prev 2005;14:805-8.
223. Fink BN, Steck SE, Wolff MS, Britton JA, Kabat GC, Gaudet MM, Abrahamson PE, Bell P, Schroeder JC, Teitelbaum SL, et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev 2007;16:2285-92.
224. dos Santos Silva I, Mangtani P, McCormack V, Bhakta D, McMichael AJ, Sevak L. Phyto-oestrogen intake and breast cancer risk in South Asian women in England: findings from a population-based case-control study. Cancer Causes Control 2004;15:805-18.
225. Peterson J, Lagiou P, Samoli E, Lagiou A, Katsouyanni K, La Vecchia C, Dwyer J, Trichopoulos D. Flavonoid intake and breast cancer risk: a case-control study in Greece. Br J Cancer 2003;89:1255-9.
226. Murkies A, dalais FS, Briganti EM, Burger HG, Healy DL, Wahlqvist ML, Davis SR. Phytoestrogen and breast cancer in postmenopausal women: a case control stuy. Menopause 2000;7.
227. Appelt LC, Reicks MM. Soy induces phase II enzymes but does not inhibit dimethylbenz(a)anthracene-induced carcinogenesis in female rats. J Nutr 1999;129:1820-6.
228. Gotoh T, Yamada K, Ito A, Yin H, Kataoka T, Dohi K. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. Jpn J Cancer Res 1998;89:487-95.
229. Hawrylewicz EJ, Zapata JJ, Blair WH. Soy and experimental cancer: Animal stuides. The Journal of Nutition 1995;125:698S-708S.
230. Ohta T, Nakatsugi S, Watanabe K, Kawamori T, Ishikawa F, Morotomi M, Sugie S, Toda T, Sugimura T, Wakabayashi K. Inhibitory effects of Bifidobacterium-fermented soy milk on 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine-induced rat mammary carcinogenesis, with a partial contribution of its component isoflavones. Carcinogenesis 2000;21:937-41.
231. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S-558S.
232. Hilakivi-Clarke L, Cho E, Onojafe I, Raygada M, Clarke R. Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol 1999;6:1089-95.
233. Ju YH, Allred KF, Allred CD, Helferich WG. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 2006;27:1292-9.